Hostname: page-component-586b7cd67f-r5fsc Total loading time: 0 Render date: 2024-11-22T08:32:45.509Z Has data issue: false hasContentIssue false
  • English
  • Français

Preventing Relapse and Recurrence of Depression: A Brief Review of Therapeutic Options

Published online by Cambridge University Press:  07 November 2014

Michael E. Thase
Get access Rights & Permissions [Opens in a new window]

Abstract

Depression is increasingly recognized as a highly recurrent and potentially chronic illness that imposes a substantial burden on individuals, families, and society. Evidence indicates that the risks of depressive recurrence, treatment resistance, and chronicity increase as the illness becomes more highly recurrent. Up to 1 year of continuation phase therapy is now recommended for virtually all depressed patients who respond to antidepressants, with a longer course of maintenance phase pharmacotherapy recommended for those who have experienced multiple episodes. Antidepressants, when effective during the acute phase of therapy, reduce the risk of depressive relapse (continuation phase) and recurrence (maintenance phase) by at least 50%. Longer-term antidepressant pharmacotherapy is most effective when the full dose of medication effective during acute-phase treatment is continued. As combined treatment with antidepressants and psychotherapy may improve shorter-term outcomes for patients with more severe recurrent depression, ongoing combined therapy may be indicated, especially for patients at particularly high risk. Approximately 5% to 10% of patients maintained on antidepressants relapse yearly, leading some to implicate tachyphylaxis. However, before attributing relapse or recurrence to diminished responsiveness to antidepressant medication at the neurochemical level, clinicians should ensure that the patient has been adherent to therapy as prescribed and consider other explanations.

Type
Supplement
Information
CNS Spectrums , Volume 11 , supplement S15: Long-Term Treatment of Patients with Recurrent Unipolar Major Depression: Evidence to Clinical Practice , December 2006 , pp. 12 - 21
Copyright
Copyright © Cambridge University Press 2006

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Kessler, RC, Berglund, P, Demler, O, et al.The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289:3095–3105.CrossRefGoogle ScholarPubMed
2.Greenberg, PE, Kessler, RC. Birnbaum, HG, et al.The economie burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry. 2003;64:1465–1475.CrossRefGoogle Scholar
3.Keller, MB, Lavori, PW, Mueller, TI, et al.Time to recovery, chronicity, and levels of psychopathology in major depression. A 5-year prospective follow-up of 431 subjects. Arch Gen Psychiatry. 1992;49:809–816.CrossRefGoogle ScholarPubMed
4.Kupfer, DJ, Frank, E, Perel, JM. The advantage of early treatment intervention in recurrent depression. Arch Gen Psychiatry. 1989;46:771–775.Google ScholarPubMed
5.Thase, ME. Relapse and recurrence of depression. An updated practical approach for prevention. In: Palmer, KJ, ed. Drug Treatment Issues in Depression. Auckland, New Zealand: Adis Books, Lippincott Williams & Wilkins; 2000;35–52.Google ScholarPubMed
6.Geddes, JR, Carney, SM, Davies, C, et al.Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet. 2003;361:653–661.CrossRefGoogle ScholarPubMed
7.Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatrie Association. Am J Psychiatry. 2000;157:1–45.Google Scholar
8.Frank, E, Kupfer, DJ, Perel, JM, et al.Three-year outeomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry. 1990;47:1093–1099.CrossRefGoogle ScholarPubMed
9.Kupfer, DJ, Frank, E, Perel, JM, et al.Five-year outeome for maintenance therapies in recurrent depression. Arch Gen Psychiatry. 1992;49:769–773.CrossRefGoogle Scholar
10.Frank, E, Kupfer, DJ, Perel, JM, et al.Comparison of full-dose versus half-dose pharmacotherapy in the maintenance treatment of recurrent depression. J Affect Disord. 1993;27:139–145.CrossRefGoogle ScholarPubMed
11.Reynolds, CF III, Perel, JM, Frank, E, et al.Three-year outeomes of maintenance nortriptyline treatment in late-life depression: a study of two fixed plasma levels. Am J Psychiatry. 1999;156:1177–1181.CrossRefGoogle ScholarPubMed
12.Reynolds, CF III, Frank, E, Perel, JM, et al.Nortriptyline and interpersonal psychotherapy as maintenance therapies for recurrent major depression: a randomized controlled trial in patients older than 59 years. JAMA. 1999;281:39–45.CrossRefGoogle ScholarPubMed
13.Doogan, DP, Caillard, V. Sertraline in the prevention of depression. Br J Psychiatry. 1992;160:217–222.CrossRefGoogle ScholarPubMed
14.Franchini, L, Gasperini, M, Perez, J, Smeraldi, E, Zanardi, R. A double-blind study of long-term treatment with sertraline or fluvoxamine for prevention of highly recurrent unipolar depression. J Clin Psychiatry. 1997;58:104–107.CrossRefGoogle ScholarPubMed
15.Franchini, L, Gasperini, M, Perez, J, Smeraldi, E, Zanardi, R. Dose-response efficacy of paroxetine in preventing depressive recurrences: a randomized, double-blind study. J Clin Psychiatry. 1998;59:229–232.CrossRefGoogle ScholarPubMed
16.Byrne, SE, Rothschild, AJ. Loss of antidepressant efficacy during maintenance therapy: possible mechanisms and treatments. J Clin Psychiatry. 1998;59:279–288.CrossRefGoogle ScholarPubMed
17.Lieb, J, Balter, A. Antidepressant tachyphylaxis. Med Hypotheses. 1984;15:279–291.CrossRefGoogle ScholarPubMed
18.Klerman, GL. Treatment of recurrent unipolar major depressive disorder. Commentary on the Pittsburgh Study. Arch Gen Psychiatry. 1990;47:1158–1162.CrossRefGoogle ScholarPubMed
19.Thase, ME, Entsuah, AR, Rudolph, RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry. 2001;178:234–241.CrossRefGoogle ScholarPubMed
20.Krupnick, JL, Sotsky, SM, Simmens, S, et al.The role of the therapeutic alliance in psychotherapy and pharmacotherapy outcome: findings in the National Institute of Mental Health Treatment of Depression Collaborative Research Program. J Consult Clin Psychol. 1996;64:532–539.CrossRefGoogle ScholarPubMed
21.Rothschild, R, Quitkin, FM. Review of the use of pattern analysis to differentiate true drug and placebo responses. Psychother Psychosom. 1992;58:170–177.CrossRefGoogle ScholarPubMed
22.Stewart, JW, Tricamo, E, McGrath, PJ, Quitkin, FM. Prophylactic efficacy of phenelzine and imipramine in chronic atypical depression: likelihood of recurrence on discontinuation after 6 months' remission. Am J Psychiatry. 1997;154:31–36.Google ScholarPubMed
23.Stewart, JW, Quitkin, FM, McGrath, PJ, et al.Use of pattern analysis to predict differential relapse of remitted patients with major depression during 1 year of treatment with fluoxetine or placebo. Arch Gen Psychiatry. 1998;55:334–343.CrossRefGoogle ScholarPubMed
24.Nierenberg, AA, Quitkin, FM, Kremer, C, Keller, MB, Thase, ME. Placebo-controlled continuation treatment with mirtazapine: acute pattern of response predicts relapse. Neuropsychopharmacology. 2004;29:1012–1018.CrossRefGoogle ScholarPubMed
25.McGrath, PJ, Stewart, JW, Quitkin, FM, et al.Predictors of relapse in a prospective study of fluoxetine treatment of major depression. Am J Psychiatry. 2006;163:1542–1548.CrossRefGoogle Scholar
26.Quitkin, FM, Rabkin, JG, Ross, D, Stewart, JW. Identification of true drug response to antidepressants. Use of pattern analysis. Arch Gen Psychiatry. 1984;41:782–786.CrossRefGoogle ScholarPubMed
27.Quitkin, FM, Stewart, JW, McGrath, PJ, et al.Columbia atypical depression. A subgroup of depressives with better response to MAOI than to tricyclic antidepressants or placebo. Br J Psychiatry Suppl. 1993;30–34.Google Scholar
28.Reimherr, FW, Amsterdam, JD, Quitkin, FM, et al.Optimal length of continuation therapy in depression: a prospective assessment during long-term fluoxetine treatment. Am J Psychiatry. 1998;155:1247–1253.CrossRefGoogle ScholarPubMed
29.Wilson, KC, Mottram, PG, Ashworth, L, Abou-Saleh, MT. Older community residents with depression: long-term treatment with sertraline. Randomised, double-blind, placebo-controlled study. Br J Psychiatry. 2003;182:492–497.CrossRefGoogle ScholarPubMed
30.Reynolds, CF III, Dew, MA, Pollock, BG, et al.Maintenance treatment of major depression in old age. N Engl J Med. 2006;354:1130–1138.CrossRefGoogle ScholarPubMed
31.Keller, MB, Kocsis, JH, Thase, ME, et al.Maintenance phase efficacy of sertraline for chronic depression: a randomized controlled trial. JAMA. 1998;280:1665–1672.CrossRefGoogle ScholarPubMed
32.Lepine, JP, Caillard, V, Bisserbe, JC, Troy, S, Hotton, JM, Boyer, P. A randomized, placebo-controlled trial of sertraline for prophylactic treatment of highly recurrent major depressive disorder. Am J Psychiatry. 2004;161:836–842.CrossRefGoogle ScholarPubMed
33.Rapaport, MH, Bose, A, Zheng, H. Escitalopram continuation treatment prevents relapse of depressive episodes. J Clin Psychiatry. 2004;65:44–49.CrossRefGoogle ScholarPubMed
34.Gelenberg, AJ, Trivedi, MH, Rush, AJ, et al.Randomized, placebo-controlled trial of nefazodone maintenance treatment in preventing recurrence in chronic depression. Biol Psychiatry. 2003;54:806–817.CrossRefGoogle ScholarPubMed
35.Weihs, KL, Houser, TL, Batey, SR, et al.Continuation phase treatment with bupropion SR effectively decreases the risk for relapse of depression. Biol Psychiatry. 2002;51:753–761.CrossRefGoogle ScholarPubMed
36.Terra, JL, Montgomery, SA. Fluvoxamine prevents recurrence of depression: results of a long-term, double-blind, placebo-controlled study. Int Clin Psychopharmacol. 1998;13:55–62.CrossRefGoogle ScholarPubMed
37.Entsuah, AR, Rudolph, RL, Hackett, D, Miska, S. Efficacy of venlafaxine and placebo during long-term treatment of depression: a pooled analysis of relapse rates. Int Clin Psychopharmacol. 1996;11:137–145.Google ScholarPubMed
38.Gilaberte, I, Montejo, AL, de la Gandara, J, et al.Fluoxetine in the prevention of depressive recurrences: a double-blind study. J Clin Psychopharmacol. 2001;21:417–424.CrossRefGoogle ScholarPubMed
39.Hochstrasser, B, Isaksen, PM, Koponen, H, et al.Prophylactic effect of citalopram in unipolar, recurrent depression: placebo-controlled study of maintenance therapy. Br J Psychiatry. 2001;178:304–310.CrossRefGoogle ScholarPubMed
40.Feiger, AD, Bielski, RJ, Bremner, J, et al.Double-blind, placebo-substitution study of nefazodone in the prevention of relapse during continuation treatment of outpatients with major depression. Int Clin Psychopharmacol. 1999;14:19–28.CrossRefGoogle ScholarPubMed
41.Zis, AP, Grof, P. Webster, M, Goodwin, FK. Prediction of relapse in recurrent affective disorder. Psychopharmacol Bull. 1980;16:47–49.Google ScholarPubMed
42.Klysner, R, Bent-Hansen, J, Hansen, HL, et al.Efficacy of citalopram in the prevention of recurrent depression in elderly patients: placebo-controlled study of maintenance therapy. Br J Psychiatry. 2002;181:29–35.CrossRefGoogle ScholarPubMed
43.Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatrie Association; 1994.Google Scholar
44.Posternak, MA, Zimmerman, M. Dual reuptake inhibitors incur lower rates of tachyphylaxis than selective serotonin reuptake inhibitors: a retrospective study. J Clin Psychiatry. 2005;66:705–707.CrossRefGoogle ScholarPubMed
45.Shelton, C, Entsuah, R, Padmanabhan, SK, Vinall, PE. Venlafaxine XR demonstrates higher rates of sustained remission compared to fluoxetine, paroxetine or placebo. Int Clin Psychopharmacol. 2005;20:233–238.CrossRefGoogle ScholarPubMed
46.Entsuah, AR, Huang, H, Thase, ME. Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo. J Clin Psychiatry. 2001;62:869–877.CrossRefGoogle ScholarPubMed
47.Simon, JS, Aguiar, LM, Kunz, NR, Lei, D. Extended-release venlafaxine in relapse prevention for patients with major depressive disorder. J Psychiatr Res. 2004;38:249–257.CrossRefGoogle ScholarPubMed
48.Diagnostic and Statistical Manual of Mental Disorders. 3rd ed text rev. Washington, DC: American Psychiatric Association; 1990.Google Scholar
49.Montgomery, SA, Entsuah, R, Hackett, D, Kunz, NR, Rudolph, RL. Venlafaxine versus placebo in the preventive treatment of recurrent major depression. J Clin Psychiatry. 2004;65:328–336.CrossRefGoogle ScholarPubMed
50.Viguera, AC, Baldessarini, RJ, Friedberg, J. Discontinuing antidepressant treatment in major depression. Harv Rev Psychiatry. 1998;5:293–306.CrossRefGoogle ScholarPubMed
51.Bockting, CL, Schene, AH, Spinhoven, P, et al.Preventing relapse/recurrence in recurrent depression with cognitive therapy: a randomized controlled trial. J Consult Clin Psychol. 2005;73:647–657.CrossRefGoogle ScholarPubMed
52.Hollon, SD, Jarrett, RB, Nierenberg, AA, Thase, ME, Trivedi, M, Rush, AJ. Psychotherapy and medication in the treatment of adult and geriatrie depression: which monotherapy or combined treatment? J Clin Psychiatry. 2005;66:455–468.CrossRefGoogle ScholarPubMed
53.Hollon, SD, DeRubeis, RJ, Shelton, RC, et al.Prevention of relapse following cognitive therapy vs medications in moderate to severe depression. Arch Gen Psychiatry. 2005;62:417–422.CrossRefGoogle ScholarPubMed
54.Paykel, ES. Cognitive therapy in relapse prevention in depression. Int J Neuropsychopharmacol. 2006;1–6.Google Scholar
55.Spanier, C, Frank, E, McEachran, AB, Grochocinski, VJ, Kupfer, DJ. The prophylaxis of depressive episodes in recurrent depression following discontinuation of drug therapy: integrating psychological and biological factors. Psychol Med. 1996;26:461–475.CrossRefGoogle ScholarPubMed
56.Post, RM. Transduction of psychosocial stress into the neurobiology of recurrent affective disorder. Am J Psychiatry. 1992;149:999–1010.Google ScholarPubMed
57.Kendler, KS, Thornton, LM, Gardner, CO. Stressful life events and previous episodes in the etiology of major depression in women: an evaluation of the “kindling” hypothesis. Am J Psychiatry. 2000;157:1243–1251.CrossRefGoogle ScholarPubMed
58.Kendler, KS, Thornton, LM, Gardner, CO. Genetic risk, number of previous depressive episodes, and stressful life events in predicting onset of major depression. Am J Psychiatry. 2001;158:582–586.CrossRefGoogle ScholarPubMed
59.Teasdale, JD, Segal, Z, Williams, JM. How does cognitive therapy prevent depressive relapse and why should attentional control (mindfulness) training help? Behav Res Ther. 1995;33:25–39.CrossRefGoogle ScholarPubMed
60.Teasdale, JD, Moore, RG, Hayhurst, H, Pope, M, Williams, S, Segal, ZV. Metacognitive awareness and prevention of relapse in depression: empirical evidence. J Consult Clin Psychol. 2002;70:275–287.CrossRefGoogle ScholarPubMed